Your fact-checks will appear here
Newer treatments for Alzheimer's disease that target amyloid.
for Alzheimer’s—chiefly plasma phosphorylated tau (p-tau) and amyloid-related ratios—have moved from research curiosities to validated clinical tools: the approved at least one plasma test in 2025–202...
Independent clinical trials specifically testing MemoBlast do not appear to exist in the public record; consumer-review coverage states explicitly that a lack of clinical trials on MemoBlast itself li...
Proven treatments for Alzheimer’s disease fall into two camps: modest symptomatic drugs that have been used for decades (cholinesterase inhibitors and memantine) and newer anti-amyloid immunotherapies...
Recent Phase III readouts show a clear group‑level relationship: antibodies that produce large, sustained reductions in amyloid PET signal have tended to produce modest but statistically significant s...
remain indispensable for mechanistic insight and early safety testing in , but their track record at predicting successful human clinical outcomes is mixed: they reproduce specific neuropathologies an...
The body of research points away from a single “toxin→symptom” pathway and toward converging neuropathological signatures—abnormal, prion‑like protein aggregates and tau‑dominated neurofibrillary tang...
A randomized phase‑2 trial of an intensive, multimodal lifestyle intervention reported measurable improvements in cognition and function after 20 weeks among people with mild cognitive impairment (MCI...